Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors

Our Bureau

Today, Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, announced the appointment of senior industry leader Eva-Lotta Allan as the Chair of its Board of Directors. The announcement comes at an important moment of growth by the company as it advances […]

Subscribe Now